Eli Lilly files trade complaint seeking to block tirzepatide imports from 11 sellers
The case accuses 11 sellers of trademark and advertising violations tied to tirzepatide products; it is not a ruling on whether the drug works or is safe.
Eli Lilly and Company has asked the U.S. International Trade Commission to bar imports of products containing or claiming to contain tirzepatide, the active ingredient in the company's Mounjaro and Zepbound. The complaint, filed Oct. 19, 2023 and supplemented on Nov. 10, 2023, names 11 sellers in the United States and overseas [1][2].
Lilly's filing accuses those sellers of breaking section 337 of the Tariff Act of 1930 in three ways: infringing U.S. Trademark Registration No. 6,809,369, falsely designating the source of goods, and running false or misleading advertising, according to the Federal Register notice of the case [2]. The remedy Lilly requested is a general exclusion order, which would keep the goods out of the country, or a narrower limited exclusion order as an alternative, plus cease and desist orders aimed at the sellers themselves [1][2].
The Commission voted on Nov. 20, 2023 to open Investigation No. 337-TA-1377. It announced the move on Nov. 21 and published formal notice in the Federal Register on Nov. 27 at 88 FR 82914 [1][2]. In its announcement, the agency stressed that starting the case decides nothing about who is right: "By instituting this investigation," it wrote, the USITC "has not yet made any decision on the merits of the case" [1].
Five of the respondents are American companies: Arctic Peptides LLC of Ankeny, Iowa; Strate Labs LLC of Spring, Texas; Supopeptide of Cedar Grove, New Jersey; Unewlife of Cedar Grove, New Jersey; and Triggered Supplements LLC, which does business as The Triggered Brand and is based in Clearwater, Florida [1]. The others are Audrey Beauty Co. and Mew Mews Company Limited, both of Hong Kong; Biolabshop Limited of Lancaster, United Kingdom; Steroide Kaufen of Bialystok, Poland; Super Human Store of Barcelona, Spain; and Xiamen Austronext Trading Co., Ltd., doing business as AustroPeptide, of Fujian, China [1].
The case covers two categories of goods: products that do contain tirzepatide and products that merely "purport" to contain it [1][2]. That second category means the investigation reaches items that may hold none of the drug at all, although the filings do not say which products fall into which group.
Once a case is instituted, the Commission's chief administrative law judge assigns it to one of the agency's judges, who schedules an evidentiary hearing and then issues an initial determination on whether section 337 was violated. The full Commission may review that finding and issues the final decision [1]. A target date for finishing the case must be set within 45 days of institution [1]. Any remedial order takes effect when issued and becomes final 60 days later, unless the U.S. Trade Representative sets it aside for policy reasons during that window [1].
Why it matters for patients
The dispute turns on branding and advertising claims, not on whether tirzepatide works or is safe; the Commission has taken no position on the merits of the allegations [1]. Nothing in the investigation concerns the supply of FDA-approved Mounjaro or Zepbound [1][2]. Products bought from the named sellers could be affected if an exclusion order is issued, because such an order blocks imports at the border, and a general order would apply beyond the specific companies named. Because the case also covers products that only claim to contain tirzepatide, the case name alone does not tell a buyer what a given product held [1][2]. How many patients purchased from these sellers, and what those products contained, has not been disclosed in the filings.
What happens next
The docket shows the case moved forward over the following year and a half: notices in May and June 2024 on motions to amend the complaint and the notice of investigation; a December 2024 request for public-interest submissions; a Jan. 28, 2025 notice that the Commission declined to review an initial determination finding respondents in violation of section 337, along with a call for written submissions on remedy, the public interest and bonding; and an April 15, 2025 notice titled "Notice of Issuance of a General Exclusion Order, a Limited Exclusion Order, and Cease and Desist Orders; Termination of the Investigation" [2]. Which respondents were found in violation, and which products the orders cover, has not been reported in these documents.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.